Skip to main content

Table 3 Burden of DPR and aDMA by region in clinicopathologic subgroups

From: Poly-GR dipeptide repeat polymers correlate with neurodegeneration and Clinicopathological subtypes in C9ORF72-related brain disease

 

FCtx

DF

CA4

CA2/3

MCtx

 

poly-GA

FTLD

6.4 (3.8, 9.4)

310 (110, 470)

6 (4.1, 9.5)

5.6 (4.5, 8.3)

5.8 (3.7, 12)

FTLD-MND

7.5 (5.6, 15)

420 (320, 630)

9.5 (6.6, 13)

9.7 (4.7, 15)

14 (6.2, 17)

MND

7.4 (5.8, 13)

380 (280, 480)

10 (7.4, 14)

8.2 (3.0, 12)

9.3 (6.5, 13)

 

poly-GP

FTLD

9.7 (5.9,14)

120 (71, 262)

8 (6.7, 13)

19 (13, 33)

10 (6.7, 13)

FTLD-MND

13 (11, 18)

180 (98, 270)

13 (7.4, 18)

31 (19, 39)

10 (8.0, 14)

MND

10 (6.6, 16)

130 (86, 230)

13 (10, 17)

27 (16, 39)

11 (4.9, 18)

 

poly-GR

FTLD

3.0 (2.2, 4.2)

16 (9.5, 48)

3.0 (2.3, 5.6)

5.1 (3.3, 9.3)

2.6 (1.3, 5.5)

FTLD-MND

6.8 (3.7, 9.5)*

49 (26, 86)*

8.5 (6.8, 12)*

17 (11, 26)*

4.7 (3.1, 7.9)

MND

2.9(1.1, 3.4)

26 (18, 51)

7.5 (4.7, 8.8)

12 (3.7, 22)

2.6 (1.2, 4.9)

 

aDMA

FTLD

3.3 (2.8, 4.7)

83 (31, 100)

10 (6.8, 14)

16 (10, 37)

3.4 (2.1, 5.6)

FTLD-MND

5.5 (3.1, 8.2)

77 (21, 140)

17 (14, 22)*

25 (17, 36)

5.6 (4.6, 6.8)

MND

4.0 (2.1, 7.4)

53 (31, 81)

15 (12, 20)

15 (6, 29)

3.5(2.5, 5.6)

  1. In frontal cortex, p < 0.001, FTLD vs. FTLD-MND, p = 0.005, FTLD-MND v.s MND. In DF, p = 0.02, FTLD vs. FTLD-MND. In CA4, p = 0.002, FTLD vs. FTLD-MND. In CA2/3, p = 0.003, FTLD vs. FTLD-MND. All variables analyzed with Kruskal-Wallis ANOVA on Ranks and data are displayed as median (25th and 75th range)
  2. *Statistically significant p-value (p < 0.05); all p-value for ANOVA on Ranks comparison of all three groups
  3. FCtx frontal cortex, MCtx Motor cortex, DF dentate fascia, CA (cornu ammonis)